Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INNOVATE: Intercalated Erlotinib and Chemotherapy in Advanced NSCLC
NCT02095782Phase 2Terminated
- Sponsor
- Guangdong Association of Clinical Trials
- Start
- Mar 2014
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Guangdong Association of Clinical Trials. Primary endpoint: Progression Free Survival at 8 weeks. Started Mar 2014; status: terminated.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02095782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02095782.